Apogee Therapeutics (NASDAQ:APGE) Upgraded at Mizuho

Apogee Therapeutics (NASDAQ:APGE) was upgraded by stock analysts at Mizuho to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

APGE has been the topic of a number of other research reports. Royal Bank Of Canada started coverage on shares of Apogee Therapeutics in a report on Thursday, September 25th. They issued an “outperform” rating and a $60.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a report on Monday, August 11th. Citigroup restated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, August 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apogee Therapeutics in a research note on Wednesday, October 8th. Finally, Bank of America lifted their price target on Apogee Therapeutics from $78.00 to $87.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Apogee Therapeutics Stock Down 4.3%

Shares of APGE opened at $53.48 on Monday. The firm has a market cap of $2.47 billion, a PE ratio of -12.95 and a beta of 1.43. The company’s fifty day moving average is $41.31 and its two-hundred day moving average is $39.37. Apogee Therapeutics has a fifty-two week low of $26.20 and a fifty-two week high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings results on Monday, August 11th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.10). As a group, equities research analysts anticipate that Apogee Therapeutics will post -3.09 earnings per share for the current year.

Insider Buying and Selling at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 5,110 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $39.80, for a total transaction of $203,378.00. Following the completion of the sale, the insider owned 284,733 shares of the company’s stock, valued at $11,332,373.40. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 10,560 shares of company stock worth $409,524. 42.77% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock worth $77,000 after purchasing an additional 272 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Apogee Therapeutics by 99.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $33,000 after purchasing an additional 383 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Apogee Therapeutics by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after purchasing an additional 694 shares during the last quarter. BNP Paribas Financial Markets grew its position in Apogee Therapeutics by 34.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock worth $158,000 after purchasing an additional 941 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in shares of Apogee Therapeutics by 13.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 8,500 shares of the company’s stock worth $369,000 after acquiring an additional 1,000 shares during the period. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.